

67383_Auto_Edited.docx

Quotes Excluded
Bibliography Excluded

5% SIMILAR

1%

1%

1%

1%

Text-Only Report

Name of Journal: World Journal of Clinical Cases

Manuscript NO: 67383

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease

Jose María Huguet, Xavier Cortés, Marta Maia Bosca-Watts, Marian Aguas, Nuria Maroto, Lidia Martí, Cirilo Amorós, Jose María Paredes

Abstract

BACKGROUND





Real-World Data on the Infliximab Biosimilar CT-P13 (Remsima®) in







ALL

IMAGES

VIDEOS

24,900 Results

Any time *

CT-P13 (Inflectra[™], Remsima[™]) monitoring in patients with ... https://pubmed.ncbi.nlm.nih.gov/27435444

The approval of **infliximab biosimilars Remsima™** and Inflectra™ (CT-P13) for patients with **inflammatory bowel disease** (IBD) is a promising step to reduce treatment costs. Since monitoring of Remicade™ serum trough levels and anti-Remicade™ immunogenicity hold an important significance in treatment modalities, no data about monitoring of drug serum trough ...

Cited by: 7 Author: Kornelius Schulze, Nadine Koppka, F...

Publish Year: 2016

Switching from Remicade® to Remsima® is well Tolerated ... https://pubmed.ncbi.nlm.nih.gov/27660339

Abstract. Background and aims: A biosimilar version of infliximab [CT-P13/Remsima®] recently entered the European market. The clinical data on its use in inflammatory bowel disease [IBD] are sparse, especially on switching from the originator Remicade®. In this study, we aimed to prospectively investigate the feasibility, safety and immunogenicity of switching from Remicade to Remsima in a real-life ...

Cited by: 97 Author: Lydia C. T. Buer, Lydia C. T. Buer, Bjø...

Publish Year: 2016

Clinical experience with infliximab biosimilar Remsima (CT ... https://www.ncbi.nlm.nih.gov/pubmed/27134662

Based on current data, CT-P13 seems to be efficacious and generally well tolerated in IBD especially in patients who are naïve to biological therapy. Knowledge with regard to interchangeability between CT-P13 and the originator infliximab is however, still rather sparse and more data are desired.

Cited by: 21 Author: Jørgen Jahnsen, Jørgen Jahnsen

Publish Year: 2016

Post-marketing analysis for biosimilar CT-P13 in ...

https://pubmed.ncbi.nlm.nih.gov/33450057

Background and aim: CT-P13, an infliximab (IFX) biosimilar, was approved for treatment of inflammatory bowel disease. However, no comparison with the originator IFX in this indication has



Microsoft Bing

国内版 国际版

Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in







Q ALL

▶ VIDEOS



26,500 Results

Any time ▼


Infliximab biosimilar CT-P13 is interchangeable with its ...

https://pubmed.ncbi.nlm.nih.gov/31422647



Cited by: 4 Author: Tomoo Nakagawa, Taku Kobayashi, Kiyo...

Publish Year: 2019





Real-world data on the infliximab biosimilar CT-P13 (Remsima)







ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

Show language tabs

7,780 Results

Any time *

Infliximab biosimilar CT-P13 is interchangeable with its ...

https://pubmed.ncbi.nlm.nih.gov/31422647

Background/aims: An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease. Methods: Patients were prospectively enrolled between November 2014 and March 2017, after the launch of CT-P13 in Japan, and case report forms of patients followed for at least 4 months ...

Author: Tomoo Nakagawa, Taku Kobayashi, Kiyohir... Cited by: 4

Publish Year: 2019

CT-P13 (Inflectra™, Remsima™) monitoring in patients with ...

https://pubmed.ncbi.nlm.nih.gov/27435444

The approval of infliximab biosimilars Remsima™ and Inflectra™ (CT-P13) for patients with inflammatory bowel disease (IBD) is a promising step to reduce treatment costs. Since monitoring of Remicade™ serum trough levels and anti-Remicade™ immunogenicity hold an important significance in treatment modalities, no data about monitoring of drug serum trough levels or anti-drug antibody ...

Cited by: 9 Author: Kornelius Schulze, Nadine Koppka, Frederik...

Publish Year: 2016

Clinical experience with infliximab biosimilar Remsima (CT ...

https://www.ncbi.nlm.nih.gov/pubmed/27134662

Based on current data, CT-P13 seems to be efficacious and generally well tolerated in IBD especially in patients who are naïve to biological therapy. Knowledge with regard to interchangeability between CT-P13 and the originator infliximab is however, still rather sparse and more data are desired.

Cited by: 21 Author: Jørgen Jahnsen, Jørgen Jahnsen

Publish Year: 2016

Switching from infliximab to biosimilar in inflammatory ...

https://journals.sagepub.com/doi/full/10.1177/1756284819842748

Apr 15, 2019 · In 2017, the extension study of PLANETRA and PLANETAS showed that switching from RP to its biosimilar CT-P13 is possible without negative effects on safety or efficacy in patients with AS. 65,66 Furthermore, switching from the IFX RP to CT-P13 after 1 year of IFX RP treatment showed continued comparable efficacy, immunogenicity and safety, to maintenance of CT-P13 treatment during the second year of the treatment 66 in PLANETRA